Rong Wan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rong Wan has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
Congying Chen
Department of Gastroenterology, Shanghai General Hospital, Shanghai, China
8 shared publicationsWenqin Xiao
Department of Gastroenterology, Shanghai General Hospital, Shanghai, China
6 shared publicationsGe Yu
Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Emergency & Crit Care Med, 100 Haining Rd, Shanghai 200080, Peoples R China
5 shared publicationsGuoyong Hu
Department of Gastroenterology, Shanghai General Hospital, Shanghai, China
5 shared publications- Guoyong Hu
Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Key Laboratory of Pancreatic Disease, Institute of Pancreatic Disease, Shanghai Jiao Tong University School of Medicine, Shanghai, China
5 shared publications Lijuan Yang
Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Gastroenterol, Sch Med, 100 Haining Rd, Shanghai 200080, Peoples R China
5 shared publications
Latest Publications
- 31 July 2024
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 48 (8) , 102431
Altered biliary microbial and metabolic profile reveals the crosstalk between NAFLD and cholelithiasis
- 31 July 2024
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 48 (8) , 102431
Altered biliary microbial and metabolic profile reveals the crosstalk between NAFLD and cholelithiasis
- Open Access
Sanguinarine Induces Necroptosis of HCC by Targeting PKM2 Mediated Energy Metabolism
Backgrounds: Abnormal metabolism is the hallmark of hepatocellular carcinoma. Targeting energy metabolism has become the major focus of cancer therapy. The natural product, sanguinarine, displays remarkable anti-tumor properties by disturbing energy homeostasis; however, the underlying mechanism has not yet been elucidated. Methods: The anticancer activity of sanguinarine was determined using CCK-8 and colony formation assay. Morphological changes of induced cell death were observed under electron microscopy. Necroptosis and apoptosis related markers were detected using western blotting. PKM2 was identified as the target by transcriptome sequencing. Molecular docking assay was used to evaluate the binding affinity of sanguinarine to the PKM2 molecule. Furthermore, Alb-CreERT2; PKM2loxp/loxp; Rosa26RFP mice was used to construct the model of HCC—through the intervention of sanguinarine in vitro and in vivo—to accurately explore the regulation effect of sanguinarine on cancer energy metabolism. Results: Sanguinarine inhibited tumor proliferation, metastasis and induced two modes of cell death. Molecular docking of sanguinarine with PKM2 showed appreciable binding affinity. PKM2 kinase activity and aerobic glycolysis rate declined, and mitochondrial oxidative phosphorylation was inhibited by sanguinarine application; these changes result in energy deficits and lead to necroptosis. Additionally, sanguinarine treatment prevents the translocation of PKM2 into the nucleus and suppresses the interaction of PKM2 with β-catenin; the transcriptional activity of PKM2/β-catenin signaling and its downstream genes were decreased. Conclusions: Sanguinarine showed remarkable anti-HCC activity via regulating energy metabolism by PKM2/β-catenin signaling. On the basis of these investigations, we propose that sanguinarine might be considered as a promising compound for discovery of anti-HCC drugs.
Open AccessSanguinarine Induces Necroptosis of HCC by Targeting PKM2 Mediated Energy Metabolism
Backgrounds: Abnormal metabolism is the hallmark of hepatocellular carcinoma. Targeting energy metabolism has become the major focus of cancer therapy. The natural product, sanguinarine, displays remarkable anti-tumor properties by disturbing energy homeostasis; however, the underlying mechanism has not yet been elucidated. Methods: The anticancer activity of sanguinarine was determined using CCK-8 and colony formation assay. Morphological changes of induced cell death were observed under electron microscopy. Necroptosis and apoptosis related markers were detected using western blotting. PKM2 was identified as the target by transcriptome sequencing. Molecular docking assay was used to evaluate the binding affinity of sanguinarine to the PKM2 molecule. Furthermore, Alb-CreERT2; PKM2loxp/loxp; Rosa26RFP mice was used to construct the model of HCC—through the intervention of sanguinarine in vitro and in vivo—to accurately explore the regulation effect of sanguinarine on cancer energy metabolism. Results: Sanguinarine inhibited tumor proliferation, metastasis and induced two modes of cell death. Molecular docking of sanguinarine with PKM2 showed appreciable binding affinity. PKM2 kinase activity and aerobic glycolysis rate declined, and mitochondrial oxidative phosphorylation was inhibited by sanguinarine application; these changes result in energy deficits and lead to necroptosis. Additionally, sanguinarine treatment prevents the translocation of PKM2 into the nucleus and suppresses the interaction of PKM2 with β-catenin; the transcriptional activity of PKM2/β-catenin signaling and its downstream genes were decreased. Conclusions: Sanguinarine showed remarkable anti-HCC activity via regulating energy metabolism by PKM2/β-catenin signaling. On the basis of these investigations, we propose that sanguinarine might be considered as a promising compound for discovery of anti-HCC drugs.
- Open Access
- 5 April 2024
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 12 (04) , E568-E569
A novel “NOTES” technique for treating incarcerated stones in the gallbladder neck
Incarceration of stones in the gallbladder neck often causes acute inflammation and, in severe cases, even pyogenic gangrene. Medical treatment is often ineffective, and guidelines recommend laparoscopic cholecystectomy (LC) as the preferred treatment within 24 to 72 hours of onset [1] [2]. However, this procedure carries a relatively high risk of adverse events, including bile duct injury, postoperative bile leakage, common bile duct stones, and other serious problems [3]. In nonsurgical patients, endoscopic options such as endoscopic ultrasound (EUS)-guided drainage with metal stents have improved the treatments that could be offered [4] [5]. In this report, we first present a novel endoscopic solution, derived from NOTES, to address stone obstruction of the gallbladder neck. A 59-year-old woman presented with right epigastric pain for 1 month, which had worsened over the past 2 days. Abdominal ultrasonography, hepatobiliary scintigraphy and EUS revealed an incarcerated stone of approximately 13×12 mm in the gallbladder neck as the underlying cause. The patient declined LC and requested preservation of her gallbladder. To address the issue, we performed endoscopic laser lithotripsy and lithotomy through a transgastric mini-incision of the cholecystic fundus ([Fig. 1], [Video 1]). During the procedure, the anterior wall of the gastric antrum was perforated with a sterile colonoscope (PCF-Q260JI, 3.2-mm channel diameter; Olympus, Tokyo, Japan). Subsequently, the gallbladder fundus was located and a 3- to 4-mm incision was made using a flush knife (Fuji, Tokyo, Japan). Incision occlusion was achieved with a lithotomy balloon (Micro-Tech, Nanjing, China) to prevent bile leakage, followed by thorough exchanges of suppurative bile with normal saline. After adequate gallbladder lavage, the incision was widened to 12 to 14 mm. Upon entering the gallbladder cavity, congestion and edema of the gallbladder wall were observed, along with an incarcerated stone embedded in the entrance to the gallbladder neck. Laser lithotripsy (U100plus lithotripter-Laser, W.O.M. WORLD OF MEDICINE AG, Berlin, Germany) was performed using a laser fiber (560 μm×3.5 m, SiliconFlex 300Rplus, Berlin, Germany) to fragment the stones, which were subsequently extracted using an extraction bag (Alton, Shanghai, China). The gallbladder cavity was flushed and biopsies of a 5-mm superficial, protuberant, red lesion were taken. Finally, the gallbladder incision was closed, the abdominal cavity was flushed, and the gastric wall was closed. The patient had an uneventful postoperative course and was discharged 3 days after the endoscopic surgery. Pathology of the gallbladder wall indicated inflammation of the cells. During the 15-month follow-up, the patient’s symptoms completely resolved, and no obvious stones were detected in her gallbladder by ultrasonography at her 1-month and 6-month follow-up visits. Thus, endoscopic laser lithotripsy and lithotomy through a transgastric mini-incision of the cholecystic fundus might offer a feasible approach for management of incarcerated stones in the gallbladder neck, especially solitary stones. Received: 07 January 2024 Accepted after revision: 26 February 2024 Article published online: 15 April 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 5 April 2024
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 12 (04) , E568-E569
Open AccessA novel “NOTES” technique for treating incarcerated stones in the gallbladder neck
Incarceration of stones in the gallbladder neck often causes acute inflammation and, in severe cases, even pyogenic gangrene. Medical treatment is often ineffective, and guidelines recommend laparoscopic cholecystectomy (LC) as the preferred treatment within 24 to 72 hours of onset [1] [2]. However, this procedure carries a relatively high risk of adverse events, including bile duct injury, postoperative bile leakage, common bile duct stones, and other serious problems [3]. In nonsurgical patients, endoscopic options such as endoscopic ultrasound (EUS)-guided drainage with metal stents have improved the treatments that could be offered [4] [5]. In this report, we first present a novel endoscopic solution, derived from NOTES, to address stone obstruction of the gallbladder neck. A 59-year-old woman presented with right epigastric pain for 1 month, which had worsened over the past 2 days. Abdominal ultrasonography, hepatobiliary scintigraphy and EUS revealed an incarcerated stone of approximately 13×12 mm in the gallbladder neck as the underlying cause. The patient declined LC and requested preservation of her gallbladder. To address the issue, we performed endoscopic laser lithotripsy and lithotomy through a transgastric mini-incision of the cholecystic fundus ([Fig. 1], [Video 1]). During the procedure, the anterior wall of the gastric antrum was perforated with a sterile colonoscope (PCF-Q260JI, 3.2-mm channel diameter; Olympus, Tokyo, Japan). Subsequently, the gallbladder fundus was located and a 3- to 4-mm incision was made using a flush knife (Fuji, Tokyo, Japan). Incision occlusion was achieved with a lithotomy balloon (Micro-Tech, Nanjing, China) to prevent bile leakage, followed by thorough exchanges of suppurative bile with normal saline. After adequate gallbladder lavage, the incision was widened to 12 to 14 mm. Upon entering the gallbladder cavity, congestion and edema of the gallbladder wall were observed, along with an incarcerated stone embedded in the entrance to the gallbladder neck. Laser lithotripsy (U100plus lithotripter-Laser, W.O.M. WORLD OF MEDICINE AG, Berlin, Germany) was performed using a laser fiber (560 μm×3.5 m, SiliconFlex 300Rplus, Berlin, Germany) to fragment the stones, which were subsequently extracted using an extraction bag (Alton, Shanghai, China). The gallbladder cavity was flushed and biopsies of a 5-mm superficial, protuberant, red lesion were taken. Finally, the gallbladder incision was closed, the abdominal cavity was flushed, and the gastric wall was closed. The patient had an uneventful postoperative course and was discharged 3 days after the endoscopic surgery. Pathology of the gallbladder wall indicated inflammation of the cells. During the 15-month follow-up, the patient’s symptoms completely resolved, and no obvious stones were detected in her gallbladder by ultrasonography at her 1-month and 6-month follow-up visits. Thus, endoscopic laser lithotripsy and lithotomy through a transgastric mini-incision of the cholecystic fundus might offer a feasible approach for management of incarcerated stones in the gallbladder neck, especially solitary stones. Received: 07 January 2024 Accepted after revision: 26 February 2024 Article published online: 15 April 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 8 January 2024
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 12 (04) , E513-E519
A safe and effective endoscopic treatment method for simple hepatic cysts (with video)
Background and study aims Symptomatic simple hepatic cysts require treatment, with several guidelines recommending laparoscopic deroofing. However, cysts located in the posterosuperior segments are considered poor candidates for this procedure. Gastrointestinal endoscopes are more flexible and able to reach less accessible areas than laparoscopes. This study aimed to evaluate the utility of endoscopic transgastric hepatic cyst deroofing (ETGHCD) for treatment of simple hepatic cysts. Patients and methods Seven patients with simple hepatic cysts were evaluated between June 2021 and October 2023. The success rate, procedure time, post-procedure length of hospital stays, complications, pathologic diagnosis, and efficacy were recorded. Results Eleven cysts in seven patients (5 men; mean age 65.5 (standard deviation [SD] 8.5) years) were successfully treated without any complications. The mean procedure time was 65.6 minutes (SD 17.2). Mean post-procedure hospitalization was 4.4 days (SD 1.0). The pathologic diagnosis of 11 cysts showed simple hepatic cysts. The size of the cysts was significantly decreased from 337.0 cm3 (SD 528.8) to 5.2 cm3 (SD 6.3) 1 month after ETGHCD. During the median 12.7-month follow-up in seven patients, the cysts showed a 99.6% reduction with no recurrence. Conclusions ETGHCD provided a feasible, safe, effective, and minimal invasive alternative approach for the treatment of simple hepatic cysts. Received: 27 October 2023 Accepted after revision: 02 January 2024 Accepted Manuscript online: 08 January 2024 Article published online: 15 April 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 8 January 2024
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 12 (04) , E513-E519
Open AccessA safe and effective endoscopic treatment method for simple hepatic cysts (with video)
Background and study aims Symptomatic simple hepatic cysts require treatment, with several guidelines recommending laparoscopic deroofing. However, cysts located in the posterosuperior segments are considered poor candidates for this procedure. Gastrointestinal endoscopes are more flexible and able to reach less accessible areas than laparoscopes. This study aimed to evaluate the utility of endoscopic transgastric hepatic cyst deroofing (ETGHCD) for treatment of simple hepatic cysts. Patients and methods Seven patients with simple hepatic cysts were evaluated between June 2021 and October 2023. The success rate, procedure time, post-procedure length of hospital stays, complications, pathologic diagnosis, and efficacy were recorded. Results Eleven cysts in seven patients (5 men; mean age 65.5 (standard deviation [SD] 8.5) years) were successfully treated without any complications. The mean procedure time was 65.6 minutes (SD 17.2). Mean post-procedure hospitalization was 4.4 days (SD 1.0). The pathologic diagnosis of 11 cysts showed simple hepatic cysts. The size of the cysts was significantly decreased from 337.0 cm3 (SD 528.8) to 5.2 cm3 (SD 6.3) 1 month after ETGHCD. During the median 12.7-month follow-up in seven patients, the cysts showed a 99.6% reduction with no recurrence. Conclusions ETGHCD provided a feasible, safe, effective, and minimal invasive alternative approach for the treatment of simple hepatic cysts. Received: 27 October 2023 Accepted after revision: 02 January 2024 Accepted Manuscript online: 08 January 2024 Article published online: 15 April 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 January 2023
- Vol. 15 (11) , 6673-6674
Shikonin induces apoptosis and necroptosis in pancreatic cancer via regulating the expression of RIP1/RIP3 and synergizes the activity of gemcitabine ( vol 9 ,pg 5507 , 2017)
[This corrects the article on p. 5507 in vol. 9, PMID: 29312502.].
- 1 January 2023
- Vol. 15 (11) , 6673-6674
Shikonin induces apoptosis and necroptosis in pancreatic cancer via regulating the expression of RIP1/RIP3 and synergizes the activity of gemcitabine ( vol 9 ,pg 5507 , 2017)
[This corrects the article on p. 5507 in vol. 9, PMID: 29312502.].
- Open Access
- 25 August 2022
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 54 (S 02) , E1045-E1046
Novel technique for treating simple hepatic cysts: endoscopic transgastric hepatic cyst deroofing
Simple hepatic cysts are common benign liver lesions which are usually asymptomatic and discovered incidentally. However, larger lesions may need surgical treatment if patients present with abdominal pain, epigastric fullness, or early satiety [1]. American Society of Gastroenterology clinical practice guidelines recommend that symptomatic simple hepatic cysts may be managed with laparoscopic deroofing rather than aspiration and sclerotherapy [2]. Natural-orifice transluminal endoscopic surgery (NOTES) has been developed as a step towards less invasive procedures [3]. With the development of digestive endoscopy, some researchers have used endoscopic ultrasound-guided fine-needle aspiration or NOTES technology for cystic fluid aspiration. Herein, we report a novel approach to smoothly achieving unroofing of simple hepatic cysts, called endoscopic transgastric hepatic cyst deroofing (ETGHCD). A 73-year-old man complained about abdominal pain and epigastric fullness, which was significantly impacting on his daily life. Abdominal computed tomography and ultrasonography revealed an 8-cm simple cyst located in the right liver as the underlying disease. To address the issue we performed ETGHCD on the patient. During the procedure the anterior wall of the gastric antrum was perforated with a sterile colonoscope. The cyst was found at the lower edge of segment IV of the liver. After endoscopic ultrasonography reconfirmed the cyst, transparent liquid was extracted with a 23-G puncture needle (Boston Scientific) and sent for examination. After all fluid was extracted from the cyst, we opened the cyst wall and removed it piecemeal with a snare at the interface with the hepatic parenchyma, sealed the vessels of the cyst wall, flushed the abdominal cavity, and closed the gastric wall. The ETGHCD technique, which was applied to the large hepatic cyst located on the surface of the liver, was performed and deroofing of the cyst was achieved, thus avoiding surgery ([Fig. 1], [Video 1]). The postoperative course was uneventful. The patient was discharged 2 days after endoscopic surgery. His symptoms resolved completely during the following 6 months. Video 1 Endoscopic transgastric hepatic cyst deroofing for the treatment of a hepatic cyst in a 73-year-old man. Endoscopy_UCTN_Code_TTT_1AT_2AF * These two authors contributed equally. Article published online: 25 August 2022 © 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 25 August 2022
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 54 (S 02) , E1045-E1046
Open AccessNovel technique for treating simple hepatic cysts: endoscopic transgastric hepatic cyst deroofing
Simple hepatic cysts are common benign liver lesions which are usually asymptomatic and discovered incidentally. However, larger lesions may need surgical treatment if patients present with abdominal pain, epigastric fullness, or early satiety [1]. American Society of Gastroenterology clinical practice guidelines recommend that symptomatic simple hepatic cysts may be managed with laparoscopic deroofing rather than aspiration and sclerotherapy [2]. Natural-orifice transluminal endoscopic surgery (NOTES) has been developed as a step towards less invasive procedures [3]. With the development of digestive endoscopy, some researchers have used endoscopic ultrasound-guided fine-needle aspiration or NOTES technology for cystic fluid aspiration. Herein, we report a novel approach to smoothly achieving unroofing of simple hepatic cysts, called endoscopic transgastric hepatic cyst deroofing (ETGHCD). A 73-year-old man complained about abdominal pain and epigastric fullness, which was significantly impacting on his daily life. Abdominal computed tomography and ultrasonography revealed an 8-cm simple cyst located in the right liver as the underlying disease. To address the issue we performed ETGHCD on the patient. During the procedure the anterior wall of the gastric antrum was perforated with a sterile colonoscope. The cyst was found at the lower edge of segment IV of the liver. After endoscopic ultrasonography reconfirmed the cyst, transparent liquid was extracted with a 23-G puncture needle (Boston Scientific) and sent for examination. After all fluid was extracted from the cyst, we opened the cyst wall and removed it piecemeal with a snare at the interface with the hepatic parenchyma, sealed the vessels of the cyst wall, flushed the abdominal cavity, and closed the gastric wall. The ETGHCD technique, which was applied to the large hepatic cyst located on the surface of the liver, was performed and deroofing of the cyst was achieved, thus avoiding surgery ([Fig. 1], [Video 1]). The postoperative course was uneventful. The patient was discharged 2 days after endoscopic surgery. His symptoms resolved completely during the following 6 months. Video 1 Endoscopic transgastric hepatic cyst deroofing for the treatment of a hepatic cyst in a 73-year-old man. Endoscopy_UCTN_Code_TTT_1AT_2AF * These two authors contributed equally. Article published online: 25 August 2022 © 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 2 August 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9, 700192
ELK3 Mediated by ZEB1 Facilitates the Growth and Metastasis of Pancreatic Carcinoma by Activating the Wnt/β-Catenin Pathway
Rapid progression and metastasis are the major causes of death in patients with pancreatic ductal adenocarcinoma (PDAC). ELK3, a member of the ternary complex factor (TCF), has been associated with the initiation and progression of various cancers. However, the role of ELK3 in PDAC is not yet fully understood. Online databases and immunohistochemistry were used to analyze the ELK3 levels in PDAC tissues. The function of ELK3 was confirmed by a series of in vivo and in vitro studies. Western blotting and immunofluorescence were used to detect the molecular mechanisms of PDAC. ChIP-qPCR was used to study the mechanism responsible for the elevation of ELK3 expression in PDAC. The ELK3 levels were higher in PDAC tissues than in adjacent normal tissues. Functionally, we demonstrated that ELK3 acted as an oncogene to promote PDAC tumorigenesis and metastasis. Further study suggested that ELK3 promoted PDAC cell migration and invasion by activating the Wnt/β-catenin pathway, and proved that ZEB1 could directly bind to the promoter of ELK3 to increase its transcription. Finally, both were associated with the patients’ clinicopathological features and worse overall survival. Conclusively, our findings enrich the role of ELK3 in PDAC, and provide potential avenues for exploring more effective biomarkers and therapeutic strategies for the treatment of PDAC.
- 2 August 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9, 700192
Open AccessELK3 Mediated by ZEB1 Facilitates the Growth and Metastasis of Pancreatic Carcinoma by Activating the Wnt/β-Catenin Pathway
Rapid progression and metastasis are the major causes of death in patients with pancreatic ductal adenocarcinoma (PDAC). ELK3, a member of the ternary complex factor (TCF), has been associated with the initiation and progression of various cancers. However, the role of ELK3 in PDAC is not yet fully understood. Online databases and immunohistochemistry were used to analyze the ELK3 levels in PDAC tissues. The function of ELK3 was confirmed by a series of in vivo and in vitro studies. Western blotting and immunofluorescence were used to detect the molecular mechanisms of PDAC. ChIP-qPCR was used to study the mechanism responsible for the elevation of ELK3 expression in PDAC. The ELK3 levels were higher in PDAC tissues than in adjacent normal tissues. Functionally, we demonstrated that ELK3 acted as an oncogene to promote PDAC tumorigenesis and metastasis. Further study suggested that ELK3 promoted PDAC cell migration and invasion by activating the Wnt/β-catenin pathway, and proved that ZEB1 could directly bind to the promoter of ELK3 to increase its transcription. Finally, both were associated with the patients’ clinicopathological features and worse overall survival. Conclusively, our findings enrich the role of ELK3 in PDAC, and provide potential avenues for exploring more effective biomarkers and therapeutic strategies for the treatment of PDAC.
- Open Access
- 1 January 2021
- Published by SAGE Publications in Cell Transplantation
- Vol. 30
Shikonin Inhibits Cholangiocarcinoma Cell Line QBC939 by Regulating Apoptosis, Proliferation, and Invasion
This study was designed to clarify whether Shikonin causes proliferation, apoptosis, and invasion in cholangiocarcinoma cells and to investigate the mechanism of action. QBC939 cells were cultured with different doses of Shikonin, and then 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium assay was used to detect cell viability. Apoptosis of cells was detected using flow cytometry with Annexin V/propidium iodide (PI) assay after being stained with Hoechst 33242. The role of Shikonin on the invasive and metastasis ability was detected using Transwell invasion assay. Real-time polymerase chain reaction and Western blotting were used to detect the expression of caspase-3, caspase-8, epidermal growth factor receptor (EGFR), and matrix metalloproteinase (MMP)-9. Shikonin inhibited proliferation and invasive ability of QBC939 cells in a dose-dependent manner; at the same time, apoptosis of cells was also observed in a concentration-dependent fashion. Moreover, Annexin V/PI assay and Transwell invasion assay results indicated that Shikonin induced apoptosis and invasion inhibitory probably due to upregulation of caspase-3 and caspase-8 expression and downregulation of MMP-9 and EGFR expression in a concentration-dependent fashion. Shikonin could enhance apoptosis and inhibit proliferation and invasion of QBC939 cells; such biological behaviors mainly occurred via upregulating the expression of caspase-3 and caspase-8 and downregulating the expression of MMP-9 and EGFR.
- 1 January 2021
- Published by SAGE Publications in Cell Transplantation
- Vol. 30
Open AccessShikonin Inhibits Cholangiocarcinoma Cell Line QBC939 by Regulating Apoptosis, Proliferation, and Invasion
This study was designed to clarify whether Shikonin causes proliferation, apoptosis, and invasion in cholangiocarcinoma cells and to investigate the mechanism of action. QBC939 cells were cultured with different doses of Shikonin, and then 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium assay was used to detect cell viability. Apoptosis of cells was detected using flow cytometry with Annexin V/propidium iodide (PI) assay after being stained with Hoechst 33242. The role of Shikonin on the invasive and metastasis ability was detected using Transwell invasion assay. Real-time polymerase chain reaction and Western blotting were used to detect the expression of caspase-3, caspase-8, epidermal growth factor receptor (EGFR), and matrix metalloproteinase (MMP)-9. Shikonin inhibited proliferation and invasive ability of QBC939 cells in a dose-dependent manner; at the same time, apoptosis of cells was also observed in a concentration-dependent fashion. Moreover, Annexin V/PI assay and Transwell invasion assay results indicated that Shikonin induced apoptosis and invasion inhibitory probably due to upregulation of caspase-3 and caspase-8 expression and downregulation of MMP-9 and EGFR expression in a concentration-dependent fashion. Shikonin could enhance apoptosis and inhibit proliferation and invasion of QBC939 cells; such biological behaviors mainly occurred via upregulating the expression of caspase-3 and caspase-8 and downregulating the expression of MMP-9 and EGFR.
- Open Access
- 8 February 2019
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 33 (4) , e22839
Neutrophil‐to‐lymphocyte ratio can specifically predict the severity of hypertriglyceridemia‐induced acute pancreatitis compared with white blood cell
Objectives: We aimed to evaluate the values of neutrophil‐to‐lymphocyte ratio (NLR) and white blood cell (WBC) in predicting severity of acute pancreatitis (AP) with different etiologies.Methods: We compared NLR and WBC levels in patients with different etiologies and AP severity. The optimal cutoff value for them to predict severe acute pancreatitis (SAP) was determined by receiver operating characteristic (ROC) curve analysis.Results: Both NLR and WBC were elevated in patients with SAP. After subgrouping AP by etiology, NLR was predictive of SAP only in hypertriglyceridemia‐induced AP (HTG‐AP), while WBC could effectively predict severity in both gallstone and HTG‐AP. The best cutoff value of WBC for predicting SAP in gallstone AP patients was 12.81 × 109/L, with sensitivity and specificity of 78.9% and 70.2%. The best cutoff value for NLR and WBC to differentiate HTG‐SAP was more than 5.88 and 15.89 × 109/L, respectively, with sensitivity and specificity of 87% and 50% for NLR and 56.5% and 75.76% for WBC.Conclusions: Our study firstly demonstrated that NLR selectively played a role in HTG‐AP, while WBC could predict the severity of both gallstone and HTG‐AP. Furthermore, we firstly elucidated that NLR was more sensitive and accurate in judging the severity of HTG‐AP compared with WBC.
- 8 February 2019
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 33 (4) , e22839
Open AccessNeutrophil‐to‐lymphocyte ratio can specifically predict the severity of hypertriglyceridemia‐induced acute pancreatitis compared with white blood cell
Objectives: We aimed to evaluate the values of neutrophil‐to‐lymphocyte ratio (NLR) and white blood cell (WBC) in predicting severity of acute pancreatitis (AP) with different etiologies.Methods: We compared NLR and WBC levels in patients with different etiologies and AP severity. The optimal cutoff value for them to predict severe acute pancreatitis (SAP) was determined by receiver operating characteristic (ROC) curve analysis.Results: Both NLR and WBC were elevated in patients with SAP. After subgrouping AP by etiology, NLR was predictive of SAP only in hypertriglyceridemia‐induced AP (HTG‐AP), while WBC could effectively predict severity in both gallstone and HTG‐AP. The best cutoff value of WBC for predicting SAP in gallstone AP patients was 12.81 × 109/L, with sensitivity and specificity of 78.9% and 70.2%. The best cutoff value for NLR and WBC to differentiate HTG‐SAP was more than 5.88 and 15.89 × 109/L, respectively, with sensitivity and specificity of 87% and 50% for NLR and 56.5% and 75.76% for WBC.Conclusions: Our study firstly demonstrated that NLR selectively played a role in HTG‐AP, while WBC could predict the severity of both gallstone and HTG‐AP. Furthermore, we firstly elucidated that NLR was more sensitive and accurate in judging the severity of HTG‐AP compared with WBC.
- Open Access
- 25 January 2018
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 22 (3) , 1864-1872
Identification of Sox6 as a regulator of pancreatic cancer development
Pancreatic cancer (PC) is an aggressive malignancy associated with a poor prognosis and low responsiveness to chemotherapy and radiotherapy. Most patients with PC have metastatic disease at diagnosis, which partly accounts for the high mortality from this disease. Here, we explored the role of the transcription factor sex‐determining region Y‐box (Sox) 6 in the invasiveness of PC cells. We showed that Sox6 is down‐regulated in patients with PC in association with metastatic disease. Sox6 overexpression suppressed PC cell proliferation and migration in vitro and tumour growth and liver metastasis in vivo. Sox6 inhibited epithelial‐mesenchymal transition (EMT), and Akt signalling. Sox6 was shown to interact with the promoter of Twist1, a helix–loop–helix transcription factor involved in the induction of EMT, and to modulate the expression of Twist1 by recruiting histone deacetylase 1 to the promoter of the Twist1 gene. Twist1 overexpression reversed the effect of Sox6 on inhibiting EMT, confirming that the effect of Sox6 on suppressing tumour invasiveness is mediated by the modulation of Twist1 expression. These results suggest a novel mechanism underlying the aggressive behaviour of PC cells and identify potential therapeutic targets for the treatment of PC.
- 25 January 2018
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 22 (3) , 1864-1872
Open AccessIdentification of Sox6 as a regulator of pancreatic cancer development
Pancreatic cancer (PC) is an aggressive malignancy associated with a poor prognosis and low responsiveness to chemotherapy and radiotherapy. Most patients with PC have metastatic disease at diagnosis, which partly accounts for the high mortality from this disease. Here, we explored the role of the transcription factor sex‐determining region Y‐box (Sox) 6 in the invasiveness of PC cells. We showed that Sox6 is down‐regulated in patients with PC in association with metastatic disease. Sox6 overexpression suppressed PC cell proliferation and migration in vitro and tumour growth and liver metastasis in vivo. Sox6 inhibited epithelial‐mesenchymal transition (EMT), and Akt signalling. Sox6 was shown to interact with the promoter of Twist1, a helix–loop–helix transcription factor involved in the induction of EMT, and to modulate the expression of Twist1 by recruiting histone deacetylase 1 to the promoter of the Twist1 gene. Twist1 overexpression reversed the effect of Sox6 on inhibiting EMT, confirming that the effect of Sox6 on suppressing tumour invasiveness is mediated by the modulation of Twist1 expression. These results suggest a novel mechanism underlying the aggressive behaviour of PC cells and identify potential therapeutic targets for the treatment of PC.